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Abstract
Sulf-2 is an endosulfatase with activity against
glucosamine-6-sulfate modifications within subregions
of intact heparin. The enzyme has the potential to mod-
ify the sulfation status of extracellular heparan sulfate
proteoglycan (HSPG) glycosaminoglycan chains and
thereby to regulate interactions with HSPG-binding pro-
teins. In the present investigation, data mining from pub-
lished studies was employed to establish Sulf-2 mRNA
upregulation in human breast cancer. We further found
that cultured breast carcinoma cells expressed Sulf-2
mRNA and released enzymatically active proteins into
conditioned medium. In two mouse models of mam-
mary carcinoma, Sulf-2 mRNA was upregulated in com-
parison to its expression in normal mammary gland.
Although mRNA was present in normal tissues, Sulf-2
protein was undetectable; it was, however, detected in
some premalignant lesions and in tumors. The protein
was localized to the epithelial cells of the tumors. In
support of the possible mechanistic relevance of Sulf-
2 upregulation in tumors, purified recombinant Sulf-2
promoted angiogenesis in the chick chorioallantoic
membrane assay.
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Introduction
Heparan sulfate proteoglycans (HSPGs) exist on cell sur-
faces and in the extracellular matrix (ECM) [1–3]. Heparan
sulfate glycosaminoglycan (GAG) chains consist of repeat-
ing disaccharide units of glucuronic/iduronic acid and glu-
cosamine in a linear chain. One or more of these chains are
attached covalently to a protein core to form the proteogly-
can. HSPGs influence a variety of biologic processes by
binding to a multiplicity of molecules. These include signal-
ing molecules such as cytokines, chemokines, growth fac-
tors, morphogens, and angiogenic factors [e.g., fibroblast
growth factors (FGFs), vascular endothelial growth factor
(VEGF), and hepatocyte growth factor (HGF)]. The di-
saccharide units of HS chains have four different sulfation
modification sites, which are substituted on the N-, 3-O, and
6-O positions of glucosamine and the 2-O position of uronic
acid residues. The binding interactions of HSPGs require spe-
cific patterns of sulfation in subregions of the HS chains (re-
viewed by Esko and Selleck [4]). Previous work, for example,
has revealed that specific sulfation patterns play an essen-
tial role in the trimolecular interaction between heparin (a struc-
tural analogue of HSPG GAG chains), FGF, and the fibroblast
growth factor receptor (FGFR) [3]. Thus, there is a requirement
for N- and 2-O-sulfate groups of heparin for binding to FGF-2,
and a requirement for 6-O-sulfate for binding to FGFR-1.
Sulfation at the 6-O position of glucosamine residues is also
required for optimal binding of VEGF, FGF-1, FGF-10, and
IL-8 to HS or heparin [5–8]. These observations indicate that
modulation of the sulfation status of HSPGs could potentially
regulate extracellular signaling.
Classic sulfatases are mainly localized in lysosomes where
they hydrolyze sulfate ester bonds from a wide variety of sub-
strates (e.g., GAGs, sulfolipids, and steroid sulfates) [9,10].
QSulf-1 is the first discovered member of a new family of
sulfatases that are targeted to the exterior of cells [11,12].
QSulf-1 was identified as a developmentally regulated protein
that modulates Wnt signaling, apparently by altering HSPG
sulfation. We previously cloned the orthologue of QSulf-1 in
mice and humans and found a closely related homologue,
called Sulf-2 [13]. The predicted proteins are 870 to 871 amino
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acids in length, with a sulfatase domain off370 residues at
the amino terminus, a basic hydrophilic domain off310 resi-
dues, and an additional sulfatase-related domain of f110
residues at the C-terminus. The proteins are endoproteo-
lytically processed in the secretory pathway through furin-
mediated cleavage. We showed that these Sulfs exhibit both
arylsulfatase activity and highly specific endoglucosamine-6-
sulfatase activity against heparin with a neutral pH optimum
[13]. Subsequently, endosulfatase activity against heparan
sulfate was demonstrated [11,14]. Recent studies have
reported that the expression of HSulf-1 can downregulate
the signaling responses of cells to several growth factors
[FGF-2, HGF, and heparin-binding epidermal growth factor
(HB-EGF)] [15–18].
Using publicly available serial analysis of gene expression
(SAGE) data, we found that the expression of Sulf-2 mRNA
is significantly higher in human breast carcinomas, brain
tumors, and colon carcinomas than in their normal counter-
part tissues [19]. The expression level of Sulf-2 is eight-fold
higher in breast carcinomas than in normal tissues. In the
present investigation, we further investigate the association
of Sulf-2 with breast carcinomas.
Materials and Methods
Preparation of Anti–Sulf-2 Polyclonal Antibodies
Polyclonal antibodies were produced by ProSci (Poway,
CA). Rabbits were immunized with KLH conjugates of three
peptides derived from the predicted sequence of HSulf-2
(H2.1: CFLSHHRLKGRFQRDRR-COOH; H2.3: GGSRALS-
NLVPKYYGQGSEAC-COOH; and H2.5: CKWPEMKRPSS-
KSLGQLWE-COOH, where C denotes the cysteine residues
added for coupling). The peptides chosen are highly homolo-
gous to the corresponding regions in MSulf-2 (15/16, 20/21,
and 18/18 identity, respectively) but lack homology to the
corresponding regions in either HSulf-1 or MSulf-1. Anti-
bodies were purified by sequential passage of the rabbit
sera through affinity columns, each consisting of one of the
peptides coupled to SulfoLink Coupling Gel (Pierce, Rock-
ford, IL), which was used according to the manufacturer’s
instructions. Antisera and purified antibody titers were de-
termined by ELISA using specific peptides, such as the
coated antigen.
Human Breast Carcinoma Cell Lines
MCF-7, BT-20, BT-549, T47-D, MDA-MB-435, MDA-
MB-453, MDA-MB-231, and SKBr3 cell lines were obtained
from Mark Sternlicht (Department of Anatomy, University of
California-San Francisco, San Francisco, CA). They were
all shown to be independent cell lines through DNA finger-
printing analysis. All cells were grown under standard con-
ditions in RPMI 1640 or DMEM with 10% fetal bovine serum
(Invitrogen, Carlsbad, CA).
Transgenic Mouse Strains
FVB/N mice expressing the oncogene Wnt1 or Neu in
mammary glands under the control of mouse mammary
tumor virus (MMTV) LTR were obtained from Jackson Lab-
oratory (Bar Harbor, ME) [20,21].
Reverse Transcription Polymerase Chain Reaction
(RT-PCR) for Detection of HSulf-2 mRNA
Total RNA was extracted from cells using RNA-Bee (Tel-
Test, Friendwood, TX). One microgram of total RNA was
applied for reverse transcription reaction in 20 ml of buffer
with oligo(dT), using Superscript II Reverse Transcriptase
(Invitrogen). The cDNA were normalized between tissues
so as to contain an equal concentration of b-actin transcripts.
Amplified were 314-bp HSulf-2 cDNA products, using the
following PCR primers: forward, 5V-GAAAAGAGGCAGATT-
CACGTCGTTTCCAG-3V; reverse, 5V-ATCTGGTGCTTCTT-
TTGGGATGCGGGAG-3V. The conditions for denaturation,
annealing, and extension of the template cDNA were as fol-
lows: 94jC for 30 seconds, 55jC for 30 seconds, and 72jC
for 1 minute, for 35 cycles. PCR products were separated
by electrophoresis on 2% agarose gels and visualized with
ethidium bromide.
Real-Time Quantitative PCR
Real-time quantitative PCR was conducted by the Bio-
molecular Resource Center at the University of California,
San Francisco. For real-time PCR detection of MSulf-2
mRNA expression, the following oligonucleotide primers
and TaqMan probe were used: forward primer, 5V-CTC-
ACGGCTCTTCCCCAAT-3V; reverse primer, 5V-TCTGG-
GTTGGGTGCATAGTTG - 3 V; p r o b e , 5 V- ( FAM ) -
CGTCCCAGCACATCACACCGAGTT-(BHQ1)-3V. Normal
mammary tissues were obtained from three independent
FVB/Nmice (143, 377, and 377 days old); hyperplastic mam-
mary tissues were obtained from three independent MMTV-
Wnt1mice (98, 121, and 176 days old); and mammary gland
tumors were obtained from five independent MMTV-Wnt1
mice (98, 121, 176, 193, and 431 days old) and from four
independent MMTV-Neu mice (377, 377, 623, and 630 days
old). As tumor formation in these two models is stochastic
and as we sought tumors of approximately equal sizes, this
necessitated the use of mice of different ages. For the Wnt1
model, the excised tumors had the following minimum and
maximum dimensions: 12  17, 9  10, 18  20, and 11 
11 mm. For the Neu tumors, the dimensions were 12  15,
15  16, 12  12, and 16  17 mm. All samples were
processed individually. Total RNA was extracted from fro-
zen mouse tissues using RNA-Bee (Tel-Test). Two micro-
grams of total RNA was used for reverse transcription
reaction in 100 ml of buffer with random hexamers, using
Superscript II Reverse Transcriptase (Invitrogen). PCR
was conducted in triplicate with 20-ml reaction volumes of
TaqMan Universal PCR Master Mix (Applied Biosystems,
Foster City, CA), 0.9 mM of each primer, 250 nM probe,
and 5 ml of cDNA. PCR was performed using the following
parameters: 95jC, 10 minutes, 1 cycle; 95jC, 15 seconds;
and 60jC, 2 minutes, 40 cycles. Analysis was carried out
using a sequence detection software (SDS 2.1) supplied
with TaqMan 7900HT (Applied Biosystems). Expression
was quantified based on the –CT for MSulf-2 expression
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relative to the expression of hypoxanthine phosphoribosyl-
transferase (HPRT).
Western Blot Analysis
Cultured human breast carcinoma cells were lysed in
RIPA buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1%
NP-40, and 0.1% sodium dodecyl sulfate (SDS)] and pro-
tease inhibitors for 2 hours and then centrifuged at 12,000g
for 20 minutes at 4jC. Cells at f80% confluency in a
185-cm2 flask were rinsed with PBS and OptiMEM (Invi-
trogen) and further cultured in 25 ml of OptiMEM at 37jC
in 5% CO2 for 72 hours. Conditioned medium (CM) from
COS-7 cells transiently transfected with MSulf-2 cDNA was
prepared as described [13]. The lysate or the CM was
separated by electrophoresis on reducing SDS–7.5% or
10% polyacrylamide gels (Bio-Rad, Hercules, CA) and then
blotted onto ProBlott membrane (Applied Biosystems).
Membranes were blocked with 5% nonfat milk/0.2% Tween
20 in PBS (PBS-T; Sigma, St. Louis, MO) and incubated
overnight with Sulf-2 antibody (H2.3 for human cells and H2.1
for COS-7 cells) in 5% nonfat milk/PBS-T. The membranes
were washed and incubated with horseradish peroxidase–
conjugated goat anti–rabbit IgG (Jackson ImmunoResearch,
West Grove, PA) before using SuperSignal West Pico
Chemiluminescent Substrate (Pierce).
Arylsulfatase Assay
A 100-fold concentrated CM derived from HSulf-2 tran-
siently transfected CHO or MCF-7 cells was dialyzed into
50 mM HEPES (pH 8.0). Sulf-2 was bound to Sulf-2 antibody
(H2.3) complexed to protein A-Sepharose beads (IPA-
400HC; RepliGen, Needham, MA) by rotation at 4jC for
2 hours and then washed with 50 mM HEPES (pH 8.0).
The resins with bound materials were mixed with 10 mM
4-methylumbelliferyl sulfate (4-MUS) and 10 mM MgCl2 in a
total volume of 30 ml. The reaction mixtures were terminated
by the addition of 100 ml of 0.5 M Na2CO3/NaHCO3 (pH 10.7)
to each 20-ml aliquot of the reactionmixture. The fluorescence
of 4-methylumbelliferone was measured on a multiwell plate
reader CytoFluorII (PerSeptive Biosystems, Framingham,
MA), with an excitation wavelength of 360 nm and an emis-
sion wavelength of 460 nm.
Immunoprecipitation
Mammary gland tumors were dissected from MMTV-Neu
transgenic mouse (456 days old, 14 mm in diameter).
Hyperplastic mammary gland and mammary gland tumors
were obtained from MMTV-Wnt1 transgenic mice (98, 112,
114, 140, and 166 days old, with dimensions of 12 17, 12
12, 14  15, 15  22, and 10  12 mm, respectively). Litter-
mate FVB/N mice were used as a source of normal mam-
mary gland. The tissues were homogenized and lysed in
RIPA buffer for 30 minutes and centrifuged at 12,000g for
20 minutes at 4jC. The Sulf-2 antibody (H2.1) or nonimmune
rabbit IgG was added to protein A-Sepharose beads for
1 hour. The antibody-complexed beads were added to
the supernatant, which contained 2.5 mg of protein, and
were incubated at 4jC for 2 hours. The immunoprecipitated
MSulf-2 was revealed by Western blot analysis to have Sulf-
2 antibody, using the procedure described above.
Immunohistochemistry
Specimens of mammary carcinoma and hyperplastic tis-
sues from a 176-day-old MMTV-Wnt1 mouse and normal
mammary gland tissues from a littermate FVB/Nmouse were
frozen in OCT embedding medium (Mile, Elkhart, IN). Ten-
micrometer frozen sections were cut and fixed in cold ace-
tone for 5 minutes. Sections were blocked with MOM mouse
Ig–blocking buffer (Vector, Burlingame, CA) for 1 hour and
with MOM diluent containing 5% normal goat serum (stain-
ing buffer) for 5 minutes. Sulf-2 antibody (H2.1; 2.5 mg/ml)
and anti–pan cytokeratin antibody (10 mg/ml; Biomeda, Fos-
ter City, CA) or anti–smooth muscle actin (SMA; 10 mg/ml;
Sigma) antibody in staining buffer were incubated with tis-
sues for 1 hour. After washing in PBS, the tissue was
incubated with a 1/1000 dilution of biotinylated goat anti–
rabbit IgG (Jackson ImmunoResearch) and Cy3 anti-
mouse IgG (Jackson ImmunoResearch) in staining buffer
for 45 minutes. After washing in PBS, the tissues were incu-
bated with a 1/1000 dilution of Cy2-SA (Jackson Immuno-
Research) in TBS for 30 minutes. Normal rabbit IgG (Zymed,
South San Francisco, CA) or mouse IgG (Zymed) is used as
negative control.
Establishment of Sulf-2 Stable Cell Line and Purification
of Sulf-2
The sequence encoding the signal peptide was removed
from the full-length HSulf-2 cDNA and substituted with a se-
quence encoding FLAG peptide. The modified cDNA was
then ligated into pSecTag2 (N-FLAG-HSulf-2; Invitrogen).
An inactive HSulf-2, in which cysteines 88 and 89 were
mutated to alanines (designated as HSulf-2DCC) [13]), was
generated by PCR-based, site-directed mutagenesis using
the Quikchange XL Site-Directed Mutagenesis kit (Stra-
tagene, La Jolla, CA). Human embryonic kidney 293 cells
were grown in DMEM containing 10% fetal calf serum in
10-cm dishes and transfected with 10 mg of plasmid vector
(293-N-FLAG-HSulf-2 or HSulf-2DCC) and pcDNA 3.1 myc-
His() using the LipofectAMINE 2000 reagent (Invitrogen)
according to the manufacturer’s instruction. Stable 293 trans-
fectants were selected with 1 mg/ml G418 (Invitrogen). The
CM derived from 293-N-FLAG-HSulf-2 or HSulf-2DCC cells
was incubated with anti–FLAG/M2 agarose beads (Sigma)
by rotation at 4jC overnight and then washed with 50 mM
Tris–HCl (pH 7.4) and 150 mM NaCl. A solution of 0.1 mg/ml
FLAG peptide (DYKDDDDK) in 50 mM Tris–HCl (pH 7.4) and
500 mM NaCl was used to elute the FLAG-tagged fusion
proteins from beads. The eluted material was concentrated
and dialyzed to 50 mM HEPES (pH 8.0) using a Centricon-30
microconcentrator (Millipore, Billerica, MA). The purity of wild-
type Sulf-2 and HSulf-2DCC was 90% and 80%, respectively,
as determined by Coomassie blue staining of SDS-PAGE
gels. The amount of Sulf-2 was quantified using the BCA
assay (Pierce), with BSA as a standard. Comparable amounts
of HSulf-2 and HSulf-2DCC were determined by performing a
capture ELISA using an anti–FLAG M2 antibody (Sigma) as
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the capture reagent and a mixture of Sulf-2 antibodies (H2.1
and H2.3) for detection.
Chick Chorioallantoic Membrane (CAM)
Angiogenesis Assay
Ten-day chicken embryo CAMs were treated with 25, 50,
or 100 ng of purified Sulf-2 or 50 ng of Sulf-2DCC in 50 ml of
50 mM HEPES (pH 8.0). Three days after treatment, 500 ml
of 4% paraformaldehyde was applied to CAMs prior to ex-
cision for counting of vessel branch points under a dissec-
tion microscope [22]. At least 10 embryos were used per
treatment group. Each experiment was performed for a mini-
mum of three times. Data were evaluated in terms of the
average number of blood vessel branch points per treatment
group ± SEM. VEGF-165 (R&D Systems) was used for as
positive control. Statistical analyses were performed using
Student’s t test.
Results
Expression of Sulf-2 mRNA and Protein in Human
Breast Cancer
We first confirmed and extended our preliminary obser-
vations on Sulf-2 expressions in breast cancer [19]. Data
mining from a recent and extensive SAGE analysis [23]
showed that there was a seven-fold increase in Sulf-2 SAGE
tags between normal breast tissues and ductal carcinoma
in situ (DCIS) tissues (P = .018), and a further increase of
three-fold between DCIS tissues and invasive ductal carci-
noma (IDC) tissues (P = .0001) (Figure 1). Although there
was an increase in Sulf-2 expression between DCIS and
IDC, one cannot infer a higher expression in carcinoma cells
of one tumor versus the other because the proportion of
transformed cells in the different tumors is not known. Fur-
ther data mining from two cDNA microarray profiling studies
[24,25] revealed upregulation of Sulf-2 transcripts in 6 of
20 human breast carcinoma specimens relative to normal
tissues and significantly higher Sulf-2 expression in estro-
gen receptor–positive breast tumors compared to receptor-
negative ones. We next asked if Sulf-2 was expressed by
human breast carcinoma cell lines. We detected Sulf-2
mRNA in three of eight human breast carcinoma cell lines
(MCF-7, BT-20, and BT-549), as determined by RT-PCR
(Figure 2). We then developed peptide-specific polyclonal
antibodies to the predicted protein to examine the expres-
sion of Sulf-2 at the protein level (Materials and Methods
section). ByWestern blot analysis with a peptide-specific anti-
body (Figure 3), we detected Sulf-2 in the CM of cells that ex-
pressedSulf-2mRNA, but not in the CMof cells lackingmRNA
(T47D, MDA-MB-435, and MDA-MB-453). The major protein
band had an apparent molecular mass of 75 kDa, with minor
species at 240 and 135 kDa. Western blot analysis of a de-
tergent extract of MCF-7 cells revealed a predominant band
at 126 kDa (not shown).
Recombinant Sulf-1 and Sulf-2 exhibit arylsulfatase
activity against the 4-MUS substrate [13]. To determine
whether native Sulf-2 from breast carcinoma cells was en-
zymatically active, we performed an arylsulfatase assay. CM
fromMCF-7 cells or HSulf-2–transfected CHO cells was col-
lected and incubated with Sulf-2 antibody coupled to pro-
tein A-Sepharose. The bead-bound material was assayed
for activity on 4-MUS. Both types of CM showed enzyme
activity, which was dependent on the volume of CM added
(Figure 4). In contrast, no activity was precipitated when a
control rabbit IgG was substituted for the specific antibody.
Expression of Sulf-2 in the Epithelium of Hyperplastic
Tissues and Tumors in Mouse Mammary Carcinoma Models
We next investigated if the increase in Sulf-2 expression
seen in human tumors and cell lines would generalize to
mammary carcinomas in mice. Therefore, we determined
whether Sulf-2 was upregulated in two morphologically and
mechanistically distinct transgenic models of mammary
carcinoma, MMTV-Wnt1 and MMTV-Neu [20,21,26]. We
Figure 1. SAGE analysis of Sulf-2 expression in human breast cancer. Data
pertinent to Sulf-2 were mined from a published SAGE analysis of human
breasts [23]. Sulf-2 tags were enumerated from 4 normal breast tissue
libraries, 7 DCIS libraries, and 12 IDC libraries. The total number of SAGE
tags in the analysis was 1.75 million. The incidences of Sulf-2 tags in the
different tissue libraries were 0.0018% (normal), 0.012% (DCIS), and 0.032%
(IDC). The graph shows the mean number of Sulf-2 tags per 100,000 total
tags from the libraries for each class of tissue. The error bars indicate SEM.
The probabilities provided in the figure and text are based on a t-test com-
parison in the source study [23].
Figure 2. Sulf-2 mRNA in human breast carcinoma cell lines. RT-PCR was
performed on cDNA that were prepared from eight human breast carcinoma
cell lines with primer pairs for Sulf-2 and -actin primer. A 314-bp HSulf-2
cDNA product (indicated by an arrow) was amplified from MCF-7, BT20, and
BT549 cells.
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used real-time PCR to measure Sulf-2 mRNA levels in
mammary tumors (MMTV-Wnt1 and MMTV-Neu mice),
mammary hyperplastic tissues (MMTV-Wnt1 mice), and
normal mammary gland tissues (FVB/N mice) and normal-
ized them to the housekeeping gene HPRT. Sulf-2 mRNA
was expressed in tumors of MMTV-Wnt1 and MMTV-Neu
transgenic mice and was increased by 3.0-fold (P = .00001)
and 7.1-fold (P = .001), respectively, compared to that in
normal mammary gland tissues (Figure 5). In contrast, Sulf-2
mRNA was present in hyperplastic tissues at the same level
as that in normal mammary glands.
We then analyzed MMTV-Wnt1 and MMTV-Neu tumors
for immunoreactive Sulf-2. Immunoprecipitation of deter-
gent lysates followed by Western blot analysis revealed the
presence of a 115-kDa protein in both types of tumors
(Figure 6A). Recombinant MSulf-2 from COS-7 cells yielded
a band at 128 kDa. The bands were absent when non-
immune IgG was substituted for the specific antibody.
N-glycanase treatment converted the 115- and 128-kDa
bands to a single species at 100 kDa (not shown),
demonstrating that the difference in molecular weight be-
tween the native and the recombinant protein was due to
differential N-glycosylation. Applying the same immunopre-
cipitation methodology, we compared Sulf-2 expression in
mammary tissues from normal FVB/N mice and MMTV-
Wnt1 transgenic mice (hyperplastic tissues and tumors).
Lysates were prepared from four independent sets of
tissues and were normalized for overall protein concentra-
tion. The Sulf-2 band was detected in the tumors in all four
cases and in hyperplastic tissues in two of four cases. In
contrast, Sulf-2 was not present in the extracts of mam-
mary gland from the four normal animals (Figure 6B).
Dilution of the tumor lysates up to eight-fold still yielded
the specific band (not shown), thus establishing that the
expression level of Sulf-2 in mammary tumors was at least
eight-fold higher on a per-milligram-of-protein basis than that
in normal mammary gland tissues (not shown). The finding
that Sulf-2 was detectable in hyperplastic tissues, but not in
normal tissues, despite similar levels of mRNAmay reflect an
increased level of translation or stability of the mRNA in
hyperplastic tissues.
By immunohistochemistry, Sulf-2 staining was evident
in hyperplastic tissues and tumors of MMTV-Wnt1 mam-
mary glands, but was undetectable in normal mammary
glands from control FVB/N mice (Figure 7). To determine
the localization of Sulf-2, we carried out two-color immuno-
fluorescence. We examined the distribution of Sulf-2 (green)
relative to cytokeratin (using a pan cytokeratin antibody, in
red) as a marker for epithelial cells, or SMA (red) as a marker
for myoepithelial cells. In hyperplastic tissues, Sulf-2 was
present in luminal epithelial cells but not in myoepithelial
cells (Figure 7). In the tumors, Sulf-2 localized to epithelial-
derived carcinoma cells. Sulf-2 was also present in mam-
mary tumors of MMTV-Neumice (not shown), as determined
by immunostaining.
Proangiogenic Activity of Sulf-2
We have shown elsewhere that recombinant Sulf-2 can
modulate the interaction of certain growth factors and che-
mokines (e.g., FGF-1, VEGF165, and SDF-1) with heparin
[27]. Thus, pretreatment of heparin with Sulf-2 prevents
the binding of each of these factors, and Sulf-2 treatment
of the preformed heparin growth factor complex of each type
mobilizes the growth factor into solution. HSPGs in the ECM
are known to sequester growth and angiogenic factors
from their signal-transducing cellular receptors (reviewed
by Bernfield et al. [28] and Vlodavsky et al. [29]). The release
Figure 3. Sulf-2 in the CM of human breast carcinoma cell lines. The CM of
the indicated breast carcinoma cell lines was collected, and Western blot
analysis with a Sulf-2 antibody (H2.3) was performed. The apparent molecu-
lar mass of the major Sulf-2 species was 72 kDa. Minor species were evident
at 135 and 240 kDa.
Figure 4. Arylsulfatase activity of Sulf-2 in MCF-7 CM. Different volumes of
CM obtained from MCF-7 cells or HSulf-2 – transfected CHO cells were
incubated with Sulf-2 antibody (H2.3) or rabbit IgG coupled to protein A
beads. Bead-bound material was tested for arylsulfatase activity against a
10-mM 4-MUS substrate. The same results were obtained from three
different experiments. (n) MCF-7 CM + Sulf-2 antibody (H2.3) beads; (5)
HSulf-2 CHO CM + Sulf-2 antibody beads; (E) MCF-7 CM + rabbit IgG
beads; (4) HSulf-2 CHO CM + rabbit IgG beads.
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of HSPG-bound factors (e.g., VEGF) through the activity of an
extracellular enzyme, such as a metalloproteinase or a hepa-
ranase, provides a mechanism for regulating tumor angio-
genesis [30–32]. In view of the activity of Sulf-2 in reversing
the binding of VEGF and other growth factors to heparin, we
hypothesized that Sulf-2 could potentially promote angiogen-
esis when exogenously provided to a tissue site with angio-
genic potential.We took advantage of theCAMassay,which is
widely used to test the angiogenic activity of exogenous factors
[33]. CAMs of 10-day-old chick embryos were subjected to
topical application of a test substance, and angiogenesis was
quantified by counting the number of blood vessel branching
points 72 hours later. CAMs exposed to recombinant HSulf-2
formed new extensive branches in a dose-dependent manner
(Figure 8). Fifty nanograms of HSulf-2 showed the maximum
activity. The activity of Sulf-2 on a per-unit-of-protein-mass
basis was comparable to that of VEGF-165, which served as a
positive control.HSulf-2DCC,whichwasmutated at two critical
cysteines and was inactive as both an arylsulfatase and a
heparin endosulfatase [13], was inactive in the CAM assay
when tested at 50 ng.
Discussion
Three broad categories of function are attributed to HSPGs:
1) assembly and integrity of basement membranes; 2) se-
questration and storage of signaling molecules (growth
factors, morphogens, angiogenic factors, and so forth) from
their site of action; and 3) coreceptors for cell surface ty-
rosine kinases [28]. Mutations in enzymes involved in the
biosynthesis of GAG chains have established that HSPGs
play essential roles in development [4,34]. The sulfation
state of the HS GAG chains strongly influences the protein
ligands with which they interact. An enormous diversity of
HS sequences is possible [3], and considerable variegation
has, in fact, been documented in normal adult tissues [35].
Furthermore, HS chains are dynamically regulated during
development and tumorigenesis [36,37], consistent with
regulatory changes in the binding of signaling molecules.
Considerable interest therefore exists in the mechanisms
that generate a diversity of GAG chains. One possible mech-
anism is through regulation of the expression of specific sulfo-
transferases [38–40]. Another potential mechanism would
be the removal of specific sulfation modifications through
the action of extracellular sulfatases. Prior to the disovery of
the Sulfs, the only known GAG sulfatases were exosul-
fatases, which remove sulfates from the nonreducing termini
of chains during catabolic breakdown in lysosomes [10]. The
Figure 5. Sulf-2 mRNA in MMTV-Wnt1 and MMTV-Neu transgenic mouse
mammary carcinoma tissues. Real-time PCR was performed on cDNA
prepared from normal mouse mammary glands (10 independent samples),
hyperplastic tissues (9), and tumors from MMTV-Wnt1 (12) and MMTV-Neu
(6) transgenic mice. Sulf-2 mRNA expression was normalized relative to
HPRT expression. Error bars indicate SEM. Statistical significance was
computer with Student’s t test.
Figure 6. Sulf-2 expression in normal mouse tissues and mammary gland tumors. Detergent lysates of the indicated tissues were subjected to immunoprecipitation
and Western blot analysis with a Sulf-2 (H2.1) antibody or normal rabbit IgG, as described in Materials and Methods section. (A) Analysis of expression in MMTV-
Neu tumor, MMTV-Wnt1 tumor, and cell extracts of COS-7 cells transfected with MSulf-2. (B) Four sets of normal mammary gland from FVB/N mouse, and
hyperplastic and tumor tissues from a littermate MMTV-Wnt1 transgenic mouse were subjected to immunoprecipitation/Western blot analysis, as described above.
Sulf-2 was detected in all of the tumors, in two of four of the hyperplastic tissues, and in none of the normal tissue extracts.
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newly discovered Sulfs fulfill requirements for enzymes that
could dynamically edit the sulfation status of HSPG chains
and thereby modulate ligand interactions.
QSulf-1 was the first member of this new class of sulfa-
tases to be discovered. Sonic hedgehog induces its expres-
sion during somite formation in the quail embryo [12]. It is
Figure 7. Sulf-2 in the epithelia of hyperplastic mammary tissues and mammary tumors. Sections of mammary tumors and hyperplastic tissues from MMTV-Wnt1
mice and normal mammary glands from FVB/N mice were processed for dual-color immunocytochemistry and bright field histology. The left column shows staining
with a Sulf-2 antibody (H2.1; green signal). The second column shows staining with anti –pan cytokeratin (keratin; epithelial cell marker) or anti –SMA
(myoepithelial cell marker) antibodies (red signal). The third column shows the overlay of the two fluorescent images. The fourth column shows a bright field image
with hematoxylin staining. Scale bar = 100 m.
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also expressed in the notochord, floor plate, and ventral
neural tube. QSulf-1 is required for the activation of MyoD.
It was initially suggested that QSulf-1 might be involved
in Wnt signaling [12]. In fact, recombinant QSulf-1 promotes
Wnt signaling in in vitro assays [11,12]. The mechanism
apparently involves the action of QSulf-1 in remodeling the
glucosamine-6-O sulfation status of HS chains, decreasing
Wnt binding to the chains and thereby allowing ligand access
to its receptors on the target cells. QSulf-1 is thought to act
on a cell autonomous basis because the recombinant protein
is restricted to the cell surface of the transfected cell and
is not secreted into the medium; moreover, HS chains are
modified only on the cell that expresses the enzyme, not on
neighboring cells [11,12]. A second example of signal en-
hancement through QSulf-1 has been reported by Viviano
et al. [14]. In this system, transfection of QSulf-1 promotes
responses of target cells to BMP through release of an
HS-bound inhibitor of BMP (noggin) from the cell surface.
Contrasting with these signal-promoting activities, Sulf-1 has
been shown to be a negative regulator of signaling for other
factors. Thus, transfection of Sulf-1 into various cell types
reduces signaling by FGF-2, HB-EGF, or HGF [15–18]. The
effects on FGF-2 signaling were predictable because the HS
coreceptor for FGFR-1 (the tyrosine kinase receptor for
FGF-2) required 6-O sulfation [5].
Sulf-1 mRNA is expressed in a number of tissues during
development [12,41]. It is upregulated in breast and brain
tumors, as determined by SAGE analysis [19]. In ovarian
tumors, however, downregulation is common in primary ovar-
ian cancer specimens relative to normal ovarian epithelial
samples [16]. Enforced expression of Sulf-1 in ovarian cancer
lines results in diminished signaling in response to FGF-2
and HB-EGF. The picture in hepatocellular carcinoma is
mixed, with decreased levels of Sulf-1 mRNA relative to
normal tissues in one third of the samples and increased
levels in the remaining two thirds [18].
In the present study, we have focused our attention on
Sulf-2. At the protein level, Sulf-2 is 63% to 65% identical to
Sulf-1 in mice and humans [13]. A survey of GenBank se-
quences reveals the existence of Sulf-2 homologues in rat
(XP230861), quail (AAV37455), zebrafish (AAR04058), and
Drosophila (EAL28608). Previously, we showed that re-
combinant Sulf-2 exhibits arylsulfatase and heparin endo-
sulfatase activities, which are indistinguishable from those of
Sulf-1 [13]. Here we report the upregulation of Sulf-2 trans-
cripts in human breast cancer tissues and in two mouse
models of mammary carcinoma. Moreover, we establish
Sulf-2 expression at the protein level in mammary hyper-
plastic and carcinoma tissues from mammary glands of
MMTV-Wnt1 transgenic mice. Immunohistochemical analy-
sis showed that expression was present in epithelial cells.
Interestingly, Sulf-2 could not be detected either by Western
blot analysis or by tissue staining in normal adult mammary
glands, although transcripts for the gene were detectable.
Examination of human breast carcinoma cell lines led to
the identification of Sulf-2 at both the mRNA and protein
levels in three of eight cell lines. Importantly, the protein and
corresponding sulfatase activity were readily detected in CM
from the positive cell lines. The protein was released into
CM in a processed form with a subunit molecular mass of
75 kDa. This compares to the 126-kDa protein observed in
cell lysates, which corresponds to precursor polypeptide
[13]. Our detection of active Sulf-2 in CM contrasts with sev-
eral reports for recombinant Sulf-1, in which the protein and
its enzymatic activity are confined to the cells that synthe-
size it [11,12,16,41].
Figure 8. Angiogenic activity of Sulf-2 in the CAM assay. Ten-day-old chicken embryo CAMs were treated with purified Sulf-2, Sulf-2DCC, or VEGF in 50 mM
HEPES (pH 8.0). Three days after the treatment, the number of vessel branch points was counted. Data were pooled from three independent experiments. Means
and SEM are shown. Statistical comparisons were performed with Student’s t test.
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The secretion of active Sulf-2 by carcinoma cells raises
the possibility that the enzyme is used by the cells to re-
model the ECM in their environment, thereby affecting
the carcinoma cells themselves or the neighboring host
cells. A strong parallelism can be drawn with mammalian
heparanase, an enzyme that is preferentially expressed in
metastatic cell lines and human tumor tissues [42,43]. Over-
expression of heparanase cDNA in nonmetastatic tumor
cells leads to increased Matrigel invasion as well as aug-
mented metastasis and tumor angiogenesis in vivo [31].
Moreover, converse effects are observed in the gene silenc-
ing of endogenous heparanase in tumor cells: reduced
invasiveness in vitro and less vascularized tumors in vivo
[30]. A hypothesis for the increased invasiveness is the
disassembly of physical barriers through the cleavage of
heparan sulfate chains by the enzyme [31]. The effects on
angiogenesis have been attributed to the ability of the en-
zyme to mobilize heparan sulfate–bound angiogenic factors
from sequestration in the ECM [44]. In contrast to hepa-
ranase, Sulf-2 is an endosulfatase that selectively acts on
glucosamine-6-sulfate units within highly sulfated subregions
of heparin and heparan sulfate [11,13,14]. As noted above,
glucosamine-6-sulfate modification is required for the high-
affinity binding of heparin chains to a number of protein li-
gands, including VEGF. A prior report demonstrated that
QSulf-1 treatment of heparin or an HSPG prevents the
binding of a Wnt ligand [11]. We have shown that Sulf-2
reverses the interaction of heparin with VEGF and other
growth factors [27]. Therefore, proangiogenic effects of
Sulf-2, which are demonstrated in the present study, are
plausibly explained by the release of VEGF or another
angiogenic factor from HSPG sequestration, thereby making
it available to act on blood vessels. Our results thus ratio-
nalize one potential mechanism by which cancer cells could
utilize Sulf-2 to favor tumor growth, namely, by promoting
tumor angiogenesis. Therefore, the upregulation of Sulf-2
expression in breast tumors (rather than Sulf-2 being merely
a correlate of tumor progression) could be mechanistically
critical for the growth of tumors. Because a myriad of extra-
cellular events are influenced by heparan sulfate interactions
with growth factors, morphogens, cell adhesion molecules,
and so forth [1], we can envisage other mechanisms by
which cancer cells could exploit the activity of Sulf-2. In this
light, it is notable that the Sulf-2 locus was recently identified
in an insertional mutagenesis screen for candidate cancer-
causing genes in malignant brain tumors [45]. Further study
of Sulf-2 role in tumor progression is clearly warranted.
References
[1] Esko JD and Lindahl U (2001). Molecular diversity of heparan sulfate.
J Clin Invest 108, 169–173.
[2] Sasisekharan R, Shriver Z, Venkataraman G, and Narayanasami U
(2002). Roles of heparan-sulphate glycosaminoglycans in cancer. Nat
Rev Cancer 2, 521–528.
[3] Gallagher JT (2001). Heparan sulfate: growth control with a restricted
sequence menu. J Clin Invest 108, 357–361.
[4] Esko JD and Selleck SB (2002). ORDEROUTOFCHAOS: assembly of li-
gand binding sites in heparan sulfate. Annu Rev Biochem 71, 435–471.
[5] Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK,
Yayon A, Linhardt RJ, and Mohammadi M (2000). Crystal structure of a
ternary FGF–FGFR–heparin complex reveals a dual role for heparin
in FGFR binding and dimerization. Mol Cell 6, 743–750.
[6] Spillmann D, Witt D, and Lindahl U (1998). Defining the interleukin-8–
binding domain of heparan sulfate. J Biol Chem 273, 15487–15493.
[7] Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, and Lindahl U
(2001). Sequence analysis of heparan sulfate epitopes with graded
affinities for fibroblast growth factors 1 and 2. J Biol Chem 276,
30744–30752.
[8] Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, and Kimata K
(2004). Characterization of growth factor –binding structures in heparin/
heparan sulfate using an octasaccharide library. J Biol Chem 279,
12346–12354.
[9] Parenti G, Meroni G, and Ballabio A (1997). The sulfatase gene family.
Curr Opin Genet Dev 7, 386–391.
[10] Hanson SR, Best MD, and Wong CH (2004). Sulfatases: structure,
mechanism, biological activity, inhibition, and synthetic utility. Angew
Chem Int Ed Engl 43, 5736–5763.
[11] Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, and Emerson
CP Jr (2003). QSulf1 remodels the 6-O sulfation states of cell surface
heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol
162, 341–351.
[12] Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, and Emerson
CP Jr (2001). Regulation of Wnt signaling and embryo patterning by an
extracellular sulfatase. Science 293, 1663–1666.
[13] Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, and Rosen
SD (2002). Cloning and characterization of two extracellular heparin-
degrading endosulfatases in mice and humans. J Biol Chem 277,
49175–49185.
[14] Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, and Saunders
S (2004). Domain-specific modification of heparan sulfate by Qsulf1
modulates the binding of the bone morphogenetic protein antagonist
Noggin. J Biol Chem 279, 5604–5611.
[15] WangS, Ai X, FreemanSD, Pownall ME, LuQ, Kessler DS, andEmerson
CP Jr (2004). QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits
fibroblast growth factor signaling in mesoderm induction and angio-
genesis. Proc Natl Acad Sci USA 101, 4833–4838.
[16] Lai J, Chien J, Staub JK, Avula R, Greene EL, Matthews TA, Smith DI,
Kaufmann SH, Roberts LR, and Shridhar V (2003). Loss of HSulf-1
upregulates heparin binding growth factor signaling in cancer. J Biol
Chem 21, 21.
[17] Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith
DI, Roberts LR, Shridhar V, Chien JR, et al. (2004). HSulf-1 modulates
HGF-mediated tumor cell invasion and signaling in head and neck
squamous carcinoma. Oncogene 23, 1439–1447.
[18] Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews
TA, Nagorney DM, Cunningham JM, Smith DI, et al. (2004). hSulf1 sul-
fatase promotes apoptosis of hepatocellular cancer cells by decreas-
ing heparin-binding growth factor signaling. Gastroenterology 126,
231–248.
[19] Morimoto-Tomita M, Uchimura K, and Rosen SD (2003). Novel extra-
cellular sulfatases: potential roles in cancer. Trends Glycosci Glyco-
technol 15, 159–164.
[20] Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, and Varmus HE
(1988). Expression of the int-1 gene in transgenic mice is associated
with mammary gland hyperplasia and adenocarcinomas in male and
female mice. Cell 55, 619–625.
[21] Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller
WJ (1992). Expression of the neu protooncogene in the mammary
epithelium of transgenic mice induces metastatic disease. Proc Natl
Acad Sci USA 89, 10578–10582.
[22] Boudreau NJ and Varner JA (2004). The homeobox transcription factor
Hox D3 promotes integrin alpha5beta1 expression and function during
angiogenesis. J Biol Chem 279, 4862–4868.
[23] Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S,
Sahin A, Baggerly K, and Aldaz CM (2004). Transcriptomic changes
in human breast cancer progression as determined by serial analy-
sis of gene expression. Breast Cancer Res 6, R499–R513 (Epub 2004
July 2006).
[24] Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A,
Dekan G, Vogl S, Kubista E, Heider KH, et al. (2004). Tissue-wide
expression profiling using cDNA subtraction and microarrays to identify
tumor-specific genes. Cancer Res 64, 844–856.
[25] Nagai MA, Da Ros N, Neto MM, de Faria Junior SR, Brentani MM,
Hirata R Jr, and Neves EJ (2004). Gene expression profiles in breast
tumors regarding the presence or absence of estrogen and progester-
one receptors. Int J Cancer 111, 892–899.
Sulf-2 and Breast Cancer Morimoto-Tomita et al. 1009
Neoplasia . Vol. 7, No. 11, 2005
[26] Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X,
Rowlands T, Egeblad M, Cowin P, Werb Z, et al. (2003). Evidence
that transgenes encoding components of the Wnt signaling pathway
preferentially induce mammary cancers from progenitor cells. Proc
Natl Acad Sci USA 100, 15853–15858.
[27] Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J,
Werb Z, and Rosen SD (2005). HSulf-2, an extracellular endoglucos-
amine-6-sulfatase, selectively mobilizes heparin-bound growth factors
and chemokines: effects on VEGF, FGF-1, and SDF-1. In press.
[28] Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J,
and Zako M (1999). Functions of cell surface heparan sulfate proteo-
glycans. Annu Rev Biochem 68, 729–777.
[29] Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, and Fuks Z
(1991). Extracellular sequestration and release of fibroblast growth fac-
tor: a regulatory mechanism? Trends Biochem Sci 16, 268–271.
[30] Edovitsky E, Elkin M, Zcharia E, Peretz T, and Vlodavsky I (2004).
Heparanase gene silencing, tumor invasiveness, angiogenesis, and
metastasis. J Natl Cancer Inst 96, 1219–1230.
[31] Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H,
Friedmann Y, Schirrmacher V, Mitrani E, and Vlodavsky I (2002). Cell
surface expression and secretion of heparanase markedly promote
tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99,
10031–10036.
[32] Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa
K, Thorpe P, Itohara S, Werb Z, et al. (2000). Matrix metalloproteinase-
9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2,
737–744.
[33] Brooks PC, Clark RAF, and Cheresh DA (1994). Requirement of vas-
cular integrin alpha v beta 3 for angiogenesis. Science 264, 569–571.
[34] Lin X (2004). Functions of heparan sulfate proteoglycans in cell signal-
ing during development. Development 131, 6009–6021.
[35] Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M,
Veerkamp JH, and van Kuppevelt TH (2002). Large, tissue-regulated
domain diversity of heparan sulfates demonstrated by phage display
antibodies. J Biol Chem 277, 10982–10986.
[36] Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF, and
Turnbull JE (1998). Structural modification of fibroblast growth factor –
binding heparan sulfate at a determinative stage of neural develop-
ment. J Biol Chem 273, 4350–4359.
[37] Jayson GC, Vives C, Paraskeva C, Schofield K, Coutts J, Fleetwood A,
and Gallagher JT (1999). Coordinated modulation of the fibroblast
growth factor dual receptor mechanism during transformation from
human colon adenoma to carcinoma. Int J Cancer 82, 298–304.
[38] Holmborn K, Ledin J, Smeds E, Eriksson I, Kusche-Gullberg M, and
Kjellen L (2004). Heparan sulfate synthesized by mouse embryonic
stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains
no N-sulfate groups. J Biol Chem 279, 42355–42358.
[39] Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, and
Rosenberg RD (1999). Expression of heparan sulfate D-glucosaminyl
3-O-sulfotransferase isoforms reveals novel substrate specificities.
J Biol Chem 274, 5185–5192.
[40] Nogami K, Suzuki H, Habuchi H, Ishiguro N, Iwata H, and Kimata K
(2004). Distinctive expression patterns of heparan sulfate O-sulfotrans-
ferases and regional differences in heparan sulfate structure in chick
limb buds. J Biol Chem 279, 8219–8229.
[41] Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, and Masu M
(2002). Identification of a novel nonlysosomal sulphatase expressed in
the floor plate, choroid plexus and cartilage. Genes Cells 7, 173–185.
[42] Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli
R, Bitan M, Pappo O, Peretz T, Michal I, et al. (1999). Mammalian
heparanase: gene cloning, expression and function in tumor progres-
sion and metastasis. Nat Med 5, 793–802.
[43] Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, and Parish
CR (1999). Cloning of mammalian heparanase, an important enzyme in
tumor invasion and metastasis [see comments]. Nat Med 5, 803–809.
[44] Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, and
Vlodavsky I (2001). Heparanase as mediator of angiogenesis: mode of
action. FASEB J 15, 1661–1663.
[45] Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF,
Uhrbom L, and Westermark B (2004). Identification of candidate
cancer-causing genes in mouse brain tumors by retroviral tagging. Proc
Natl Acad Sci USA 101, 11334–11337.
1010 Sulf-2 and Breast Cancer Morimoto-Tomita et al.
Neoplasia . Vol. 7, No. 11, 2005
